Expert opinion on priority risk groups for influenza vaccination
This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.
Interim technical guidance on public health use of influenza antivirals during influenza pandemics
Antiviral drugs are an important addition to the public health arsenal against influenza. This interim guidance discusses the options for their effective use, especially during a pandemic.
Interim technical guidance on use of specific pandemic influenza vaccines during the H1N1 2009 pandemic
This interim guidance outlines the possible strategies that countries may wish to adopt in the deployment of a pandemic-specific vaccine, considering the two objectives of vaccination: protecting those at greatest risk of severe disease and maintaining essential services.
Interim ECDC public health guidance on case and contact management for the new influenza A(H1N1) virus infection
ECDC intends to produce a series of interim guidance documents on suggested procedures to be put in place in order to reduce the risk of transmission of the new influenza A(H1N1) virus. This guidance only applies to a situation when there are relatively few persons under investigation, and will be revised if there seems to be a wider spread.
Technical guidance on mitigation and delaying (or ‘containment’)strategies as the new influenza A(H1N1) virus comes into Europe
As epidemics of the new influenza A(H1N1) virus are extending globally, some European countries are considering how robustly to undertake case-finding among the first cases and whether to pursue and treat contacts.
Systematic review on the incubation and infectiousness/shedding period of communicable diseases in children
Illnesses caused by infectious diseases are common in children in schools or other childcare settings. Currently there is no common EU approach to the control of communicable diseases in schools or other childcare settings, and existing information is uncertain.
A network strategy to advance public health in Europe
Semenza, J.C., Apfel, F., Rose, T., Giesecke, J.
Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.